Categories: All postsAnalysts

Difference Capital has a 200 per cent upside, Mackie Research says

Difference Capital Executive Chairman & co-Founder Mike Wekerle.

Even with Canada’s so-so tech IPO environment, venture capital and private equity company Difference Capital Financial (Difference Capital Stock Quote, Chart, News: TSX:DCF) should outperform over the near term, says analyst Nikhil Thadani of Mackie Research Capital, who on Tuesday reiterated his “Buy” rating and $9.00 target for DCF.

Difference Capital reported its fourth quarter and full-year ended December 31, 2017, financials on Monday, posting a net loss for the year of $1.2 million or $0.20 per share, compared to a net loss of $12.9 million or $2.20 per share for the previous year. The company also reported Q4 net asset value of $7.74 per share, an increase over Q3/17’s $7.04 per share.

Despite the small number of 2017 IPOs in DCF’s tech and media wheelhouse, the company says that it’s looking ahead to 2018 and primarily focusing on the overall liquidity of its balance sheet.

“We continue to believe our $67 million portfolio of late stage private and early stage public technology, media and healthcare companies is well positioned for growth and liquidity events,” the company said in a press release. “Technology investments like Mogo Technologies, Vision Critical, Vena Solutions, Ethoca, and Hootsuite are all seeing strong growth and are well-funded. Our media investments like Blue Ant Media are well positioned in a rapidly digitizing media market, and our medical device companies like Cardiac Dimensions and Brainscope are well along the path of commercialization.”

Thadani says he expects DCF to trade up on more liquidity improvement since this past week.

“DCF now trades at <40 per cent reported NAV, the lowest level in ~5 1⁄2 years,” said the analyst in an update to clients. “Even with our estimated Q1/18 NAV re-trace (accounting mark to market driven) of ~$1/sh, the stock trades at the lowest level relative to NAV in over two years.”

“The company indicated a pro forma cash, cash equivalents and distributions receivable position of ~$26 million (we expect a tax bill to be paid in H1/18 in addition to opex and Q1 debt service),” said the analyst. “As such, we suspect DCF could find additional liquidity in the ~$5 million range, given the current portfolio of ~$70 million — perhaps via debt extension and/or refinancing. As such, the probability of DCF meeting debt obligations with common shares (dilutive given NAV discount and therefore an overhang on the stock) is the least since we launched coverage in early 2016.”

Thadani’s $9.00 target price represents a 200 per cent return on investment at the time of publication.

More Cantech Analysts

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: dcf
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

16 hours ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

17 hours ago

Is GOOGL still a buy?

Following a widely applauded first quarter beat, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Alphabet (Alphabet… [Read More]

2 days ago

NLH has 173% upside, Echelon says

Following an acquisition, Echelon Capital Markets analyst Stefan Quenneville has maintained his "Buy" rating on Nova Leap Health (Nova Leap… [Read More]

2 days ago

Shopify upgraded to “Buy” at Citi

The stock has been flat since November, but Citi analyst Tyler Radke thinks there is now money to be made… [Read More]

2 days ago

Sabio has 400% upside, Eight Capital says

Following the company's fourth quarter results, Eight Capital analyst Kiran Sritharan has maintained his "Buy" rating on Sabio Holdings (Sabio… [Read More]

4 days ago